Public Employees Retirement Association of Colorado increased its position in Gilead Sciences (NASDAQ:GILD) by 5.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 776,270 shares of the biopharmaceutical company’s stock after purchasing an additional 40,049 shares during the quarter. Public Employees Retirement Association of Colorado owned approximately 0.06% of Gilead Sciences worth $55,612,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Welch Investments LLC acquired a new position in Gilead Sciences in the 3rd quarter valued at about $108,000. Wealthcare Advisory Partners LLC acquired a new position in Gilead Sciences in the 3rd quarter valued at about $133,000. Horan Capital Advisors LLC. acquired a new position in Gilead Sciences in the 3rd quarter valued at about $144,000. Hanson & Doremus Investment Management grew its stake in Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 1,613 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new position in Gilead Sciences in the 2nd quarter valued at about $147,000. 77.91% of the stock is currently owned by institutional investors.
A number of research analysts recently commented on GILD shares. Leerink Swann reiterated a “market perform” rating and issued a $80.00 price target (down previously from $83.00) on shares of Gilead Sciences in a research note on Thursday, February 22nd. Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. ValuEngine upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. Credit Suisse Group set a $80.00 price target on shares of Gilead Sciences and gave the company a “hold” rating in a research note on Wednesday, January 3rd. Finally, Wells Fargo upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their price target for the company from $79.02 to $96.00 in a research note on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of “Buy” and an average target price of $88.61.
Shares of Gilead Sciences stock traded down $1.41 on Friday, reaching $73.41. 6,439,529 shares of the stock were exchanged, compared to its average volume of 6,802,121. Gilead Sciences has a one year low of $63.76 and a one year high of $89.54. The company has a current ratio of 2.74, a quick ratio of 2.67 and a debt-to-equity ratio of 1.53. The company has a market cap of $97,554.05, a PE ratio of 8.58, a price-to-earnings-growth ratio of -1.72 and a beta of 1.19.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The company had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. During the same quarter in the prior year, the firm posted $2.70 EPS. The firm’s quarterly revenue was down 18.7% on a year-over-year basis. research analysts forecast that Gilead Sciences will post 6.21 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Thursday, March 29th. Stockholders of record on Friday, March 16th were issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.11%. The ex-dividend date of this dividend was Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio is 26.64%.
In related news, Director Gayle E. Wilson sold 60,000 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $77.92, for a total value of $4,675,200.00. Following the completion of the transaction, the director now owns 182,258 shares of the company’s stock, valued at approximately $14,201,543.36. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP James R. Meyers sold 100,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $80.24, for a total transaction of $8,024,000.00. Following the completion of the transaction, the executive vice president now directly owns 102,715 shares of the company’s stock, valued at approximately $8,241,851.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 426,934 shares of company stock valued at $33,847,101. 1.30% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/public-employees-retirement-association-of-colorado-buys-40049-shares-of-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.